Kurihara Shigekazu, Sawa Naoki, Sumida Keiichi, Ikuma Daisuke, Oba Yuki, Mizuno Hiroki, Sekine Akinari, Yamanouchi Masayuki, Hasegawa Eiko, Suwabe Tatsuya, Urakami Shinji, Kono Kei, Kinowaki Keiichi, Ohashi Kenichi, Yamaguchi Yutaka, Ubara Yoshifumi
Nephrology Center and the Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Tokyo, Japan.
Department of Urology, Toranomon Hospital, Tokyo, Japan.
Front Nephrol. 2024 Jul 29;4:1409098. doi: 10.3389/fneph.2024.1409098. eCollection 2024.
A kidney biopsy was performed in a 64-year-old woman with type 2 diabetes mellitus and less than 1 g of proteinuria who rapidly progressed to end-stage renal failure after approximately 2 years of treatment with two dipeptidyl peptidase 4 (DPP-4) inhibitors for type 2 diabetes mellitus. The biopsy revealed not only a coincidental diagnosis of renal cell carcinoma, which was not evident on pre-biopsy computed tomography, but also severe thrombotic microangiopathy (TMA)-like glomerular endothelial cell damage in the noncancerous areas. These results suggest that DPP4 inhibitors may have been involved in two kidney diseases.
对一名64岁的2型糖尿病女性患者进行了肾活检,该患者蛋白尿少于1g,在用两种二肽基肽酶4(DPP-4)抑制剂治疗2型糖尿病约2年后迅速进展为终末期肾衰竭。活检不仅意外发现了肾细胞癌(活检前的计算机断层扫描未显示),还发现非癌区域存在严重的血栓性微血管病(TMA)样肾小球内皮细胞损伤。这些结果表明,DPP4抑制剂可能与两种肾脏疾病有关。